-
Company Insights
Catalyst Monitor: Q4 2026 Outlook
This report compiles published, predictive intelligence based on interviews with key opinion leaders (KOLs) on market-moving events that are expected to occur in Q4 2026. GlobalData’s latest report, “Catalyst Monitor Q4 2026”, delivers forward-looking intelligence derived from interviews with key opinion leaders (KOLs), covering trial initiations, completions, Phase III trial results, PDUFA dates, and regulatory filings. The report covers 26 significant catalyst events that are expected to occur in Q4 2026. Some of the catalysts covered in the report, include...
-
Product Insights
Lupus Nephritis: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Lupus Nephritis - Global Clinical Trials Review, 2026" provides an overview of Lupus Nephritis Clinical trials scenario. This report provides top line data relating to the clinical trials on Lupus Nephritis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
IgA Nephropathy (Berger's Disease): Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “IgA Nephropathy (Berger's Disease) - Global Clinical Trials Review, 2026" provides an overview of IgA Nephropathy (Berger's Disease) Clinical trials scenario. This report provides top line data relating to the clinical trials on IgA Nephropathy (Berger's Disease). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
Lennox-Gastaut Syndrome: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Lennox-Gastaut Syndrome - Global Clinical Trials Review, 2026" provides an overview of Lennox-Gastaut Syndrome Clinical trials scenario. This report provides top line data relating to the clinical trials on Lennox-Gastaut Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Pulmonary Tuberculosis: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Pulmonary Tuberculosis - Global Clinical Trials Review, 2026" provides an overview of Pulmonary Tuberculosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Pulmonary Tuberculosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Sicca Syndrome (Sjogren): Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Sicca Syndrome (Sjogren) - Global Clinical Trials Review, 2026" provides an overview of Sicca Syndrome (Sjogren) Clinical trials scenario. This report provides top line data relating to the clinical trials on Sicca Syndrome (Sjogren). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Sector Analysis
Dyslipidemia: Epidemiology Report and Forecast to 2035
Dyslipidemia is a medical condition characterized by abnormal lipid levels in the bloodstream, and includes the imbalance of cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), and high-density lipoprotein cholesterol (HDL-C) (Pappan, Awosika and Rehman, 2024; Roland, 2026). Dyslipidemia increases the risk of cardiovascular disease (CVD), and has been associated with multiple diseases, including type 2 diabetes (T2D), neurodegenerative diseases, and cancer (Zhu et al., 2024). Dyslipidemia is classified into primary dyslipidemia and secondary dyslipidemia. Primary dyslipidemia refers to dyslipidemia caused...
-
Thematic Analysis
Rare Diseases: Innovation, Investment, and Unmet Needs - Strategic Intelligence
Rare disease is a large, structurally underserved market. Development activity is heavily weighted to oncology, but oncology is also the least mature part of the pipeline. Dealmaking in rare disease has accelerated sharply, with 2026 already the biggest year on record for M&As. Orphan drug designations keep climbing, but regulatory approval does not guarantee patients can actually get the drug.
-
Sector Analysis
Bio/Pharmaceutical Outsourcing Report, August 2026
The Bio/Pharmaceutical Outsourcing Report is a monthly analysis of news and trends affecting pharmaceutical Contract Manufacturing Organizations (CMOs). It includes in-depth analyses of the latest business conditions, lists new outsourcing contracts, assesses the latest opportunities and threats for manufacturers, and identifies recent mergers, acquisitions, and financing among CMOs. It also updates readers on facility-level news, such as planned site openings and closures, Good Manufacturing Practice (GMP) inspections, and investments in technology and equipment.
-
Sector Analysis
Small-Cell Lung Cancer (SCLC): Market View, Current and Future Competitive Landscape
This report provides a data-driven overview of the current and future competitive landscape in Small-Cell Lung Cancer (SCLC) Therapeutics. - In 2025, there were 232,630 diagnosed prevalent cases of SCLC in the 16 countries covered in GlobalData’s epidemiology forecast. - Over the past decades, the SCLC treatment landscape was dominated by Etoposide and Platinum (EP), with few and only modestly effective relapse treatments and minimal therapeutic differentiation. Currently, adding PD‑L1 inhibitors to chemotherapy is the standard first-line approach in Extensive...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.